Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings (Q45749020)

15 December 2017

title

Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings (English)

1 reference

15 December 2017

1 reference

Marchetti A

1

1 reference

15 December 2017

Lau H

2

1 reference

15 December 2017

Magar R

3

1 reference

15 December 2017

Wang L

4

1 reference

15 December 2017

Devercelli G

5

1 reference

15 December 2017

publication date

1 April 1999

1 reference

15 December 2017

published in

Clinical Therapeutics

1 reference

15 December 2017

volume

21

1 reference

15 December 2017

issue

4

1 reference

15 December 2017

page(s)

752-766

1 reference

15 December 2017

The morality of efficiency in health care--some uncomfortable implications

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

National surveillance for respiratory syncytial virus, United States, 1985-1990.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

Local variability in respiratory syncytial virus disease severity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

Severity of respiratory syncytial virus infection is related to virus strain

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

Variation in severity of respiratory syncytial virus infections with subtype

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

Infant respiratory function after RSV-proven bronchiolitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

Respiratory syncytial virus-immunoglobulin intravenous (RSV-IGIV) for respiratory syncytial viral infections: part I.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

Birth weight and hospital readmission of infants born prematurely

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

Viral etiology and epidemiology of acute lower respiratory tract infections in Korean children.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

The Tucson Children's Respiratory Study. II. Lower respiratory tract illness in the first year of life

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

Increased incidence of bronchial reactivity in children with a history of bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

Asthma and wheezing in the first six years of life. The Group Health Medical Associates

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

RSV and chronic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

Economic impact of viral respiratory disease in children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988326-5

7 January 2021

10.1016/S0149-2918(00)88326-5

Identifiers

DOI

1 reference

15 December 2017

PubMed ID

10363740

1 reference

15 December 2017